Advanced microfluidic platforms for scalable lipid nanoparticle manufacturing and nucleic acid delivery applications.
Microfluidic technology has emerged as the gold standard for producing uniform, high-quality lipid nanoparticles (LNPs) for nucleic acid therapeutics. The precise control over mixing dynamics offered by microfluidic systems enables superior reproducibility in particle size distribution, encapsulation efficiency, and batch-to-batch consistency compared to conventional bulk mixing methods. However, selecting the appropriate microfluidic configuration, optimizing critical process parameters, and translating laboratory-scale success to manufacturing scale remain significant challenges for many development programs. BOC Sciences provides comprehensive microfluidic LNP production services, offering access to multiple mixing platforms, systematic parameter optimization, and scalable manufacturing capabilities. Our team of experienced formulation scientists and process engineers leverages advanced Design of Experiment (DoE) methodologies to rapidly identify optimal operating conditions and deliver production-ready processes that meet your quality and throughput requirements.
Microfluidic RNA LNP Formulation ProcessWe operate a comprehensive suite of microfluidic mixing platforms to address diverse formulation requirements and production scales. Our equipment portfolio includes industry-leading systems optimized for both research development and commercial manufacturing applications.
The staggered herringbone micromixer generates chaotic advection through geometrically induced flow bifurcation, achieving rapid and uniform mixing at low Reynolds numbers. This platform is particularly effective for applications requiring tight control over particle size distribution and encapsulation efficiency.
Dean flow mixers leverage secondary flow patterns induced by channel curvature to achieve efficient mixing without the need for complex geometric structures. This platform offers advantages for applications requiring high throughput and reduced pressure drop.
T-junction and hydrodynamic flow focusing configurations offer alternative mixing paradigms for specialized formulation requirements. These platforms are particularly useful for applications with specific viscosity constraints or when rapid mixing is less critical.
For accelerated formulation development, we offer automated high-throughput microfluidic screening platforms capable of testing hundreds of formulation conditions in parallel.
Beyond laboratory development, we provide access to production-scale microfluidic systems designed for commercial manufacturing.
For unique formulation challenges requiring specialized mixing configurations, we offer custom microfluidic chip design and fabrication services.
Achieving optimal LNP quality through microfluidic production requires systematic optimization of multiple interconnected parameters. Our team applies advanced DoE methodologies and process analytical technologies to accelerate development timelines while ensuring robust, scalable processes.
Partner with us to leverage advanced microfluidic platforms and expert process optimization for rapid, scalable LNP production. From feasibility to large-scale production.
Translating laboratory-scale microfluidic success to manufacturing production presents unique challenges. Our team applies rigorous scale-up principles and provides comprehensive technology transfer support to ensure consistent product quality across all production scales.
| Scale Level | Typical Capacity | Applications |
|---|---|---|
| Research Scale | 0.1-5 mL/min total flow rate | Feasibility studies, early formulation screening, assay development |
| Development Scale | 5-50 mL/min total flow rate | Process optimization, scale-up studies, toxicology batches |
| Pilot Scale | 50-500 mL/min total flow rate | Process validation, scale-up verification |
| Commercial Scale | 500 mL/min - 1 L/min (single stream) | Product supply, technology transfer |
Our microfluidic production platforms support the full spectrum of LNP applications for nucleic acid therapeutics and vaccines.
mRNA Therapeutics
Production of LNP formulations for mRNA vaccines and therapeutics, including nucleoside-modified mRNA (n1-methylpseudouridine) and self-amplifying mRNA constructs. Optimized for high encapsulation efficiency and mRNA integrity.
Manufacturing of lipid nanoparticles for short interfering RNA and antisense oligonucleotide delivery. Formulations optimized for liver targeting and enhanced cellular uptake.
Vaccine-grade LNP production for antigen-encoding mRNA and immunomodulatory oligonucleotide applications. Process optimization for enhanced immunogenicity.
Specialized production for CRISPR components including Cas9 mRNA and guide RNA. Support for both mRNA and RNP modalities in gene editing applications.
Adaptation of microfluidic processes for non-nucleic acid payloads including therapeutic peptides and proteins. Modified lipid compositions for enhanced cargo loading.
Multi-Component Systems
Production of LNP formulations co-encapsulating multiple payload types for combination therapy applications. Advanced mixing strategies for complex formulation requirements.
Even with advanced platforms, microfluidic LNP production presents unique challenges that require systematic understanding and mitigation strategies.
Comprehensive quality control ensures that all microfluidic-produced LNP batches meet specifications for critical quality attributes.
Particle Characterization
Comprehensive particle characterization including size distribution (DLS, NTA), morphology (Cryo-TEM), zeta potential, and stability assessment.
Encapsulation Analysis
Validated encapsulation quantification using RiboGreen/PicoGreen assays, SEC, and orthogonal methods for nucleic acid content verification.
Stability Testing
Accelerated and real-time stability studies to predict shelf-life and identify optimal storage conditions for formulated LNPs.
We evaluate your payload characteristics, quality requirements, and scale targets to recommend optimal microfluidic platforms and identify critical formulation parameters for development.
Systematic DoE-based optimization of microfluidic parameters and formulation composition to establish robust operating ranges and identify optimal production conditions.
Execution of scale-up studies using defined principles, verification of process performance at target scales, and validation of analytical methods for release testing.
Large-scale production with comprehensive documentation package for technology transfer to your manufacturing site or continued supply under quality management systems.
Challenge: A vaccine development company needed to produce mRNA-LNP formulations at 100 mL scale, but their laboratory-scale microfluidic process showed significant variability when attempted at the larger scale.
Solution: BOC Sciences conducted a comprehensive scale-up study using a systematic approach. First, we performed detailed characterization of the laboratory-scale process, establishing baseline particle size (85 nm), PDI (0.08), and encapsulation efficiency (92%). Next, we applied dimensional analysis to identify the critical scale-up parameters, specifically maintaining a constant specific energy input of 105 J/m3 across scales. For the 100 mL/min production, we selected a Dean flow mixer configuration that offered superior scalability compared to the staggered herringbone geometry used at laboratory scale. During optimization, we identified that increasing total flow rate from 10 mL/min to 120 mL/min while maintaining a flow rate ratio of 1:3 required adjustment of the mixing channel geometry to prevent excessive pressure buildup while preserving mixing efficiency.
Result: The scaled process achieved consistent particle size of 88 nm (±2 nm), PDI below 0.10, and encapsulation efficiency of 91% (±1.5%) across 10 consecutive batches. The process was successfully transferred with validated operating ranges established for all critical process parameters. Total timeline from feasibility to large-scale production was 4 months.
Challenge: A biotech company developing an siRNA therapeutic for liver targets needed to screen 200 formulation variations to identify optimal lipid compositions for their specific siRNA sequence, but traditional one-at-a-time optimization would require 6+ months.
Solution: Our team deployed a high-throughput microfluidic screening platform combined with automated DoE design. We programmed a systematic screening matrix varying ionizable lipid type (MC3, SM-102, LP03), helper lipid ratio (DSPC:Cholesterol from 10:40 to 15:50), and PEG-lipid content (1.0-2.0 mol%). Using nanoliter-scale experiments with inline DLS analysis, we completed 200 formulation screens in 2 weeks. Machine learning-assisted data analysis identified three promising formulation regions, which were then validated using standard milliliter-scale microfluidic production.
Result: The screening identified an optimized SM-102-based formulation with DSPC:Cholesterol ratio of 12:45 and 1.5 mol% PEG-lipid that demonstrated 94% encapsulation efficiency, 78 nm particle size, and significantly enhanced gene silencing compared to the initial reference formulation. The total development timeline was reduced from 6 months to 6 weeks.
Multiple Platform OptionsAccess to staggered herringbone, Dean flow, and flow focusing platforms ensures optimal configuration selection for your specific formulation requirements and scale targets.
High-Throughput CapabilityAutomated screening platforms combined with DoE methodologies accelerate development timelines, enabling identification of optimal formulations in weeks rather than months.
Scale-Up ExpertiseProven scale-up methodologies based on dimensional analysis and process validation ensure consistent product quality from laboratory to commercial manufacturing.
Integrated ServicesFrom Lipid Nanoparticle Formulation to Lipid Nanoparticle Encapsulation, we provide end-to-end services that streamline your development program.
Production CapabilitiesLarge-scale production capabilities support material and commercial supply under comprehensive quality management systems.
Compared with traditional liposome preparation methods such as thin-film hydration and ethanol injection, microfluidic technology offers significant advantages in LNP production. First, microfluidics enables rapid mixing at the millisecond scale, ensuring a uniform and controllable assembly process between nucleic acids and lipids, resulting in nanoparticles with narrow size distribution and strong batch-to-batch consistency. Second, by adjusting microfluidic chip geometry and operating flow rates, key particle attributes such as particle size, polydispersity index (PDI), and encapsulation efficiency can be precisely controlled. Third, microfluidic systems are easy to scale linearly by increasing the number of chip channels or using parallel arrays, enabling a smooth transition from laboratory-scale preparation to larger-scale production. In addition, the low-shear mixing environment helps protect sensitive nucleic acid payloads. BOC Sciences provides microfluidic production platforms in multiple specifications and can customize solutions according to each client’s project needs.
Key process parameters in microfluidic LNP production mainly include the flow rate ratio (FRR, the volumetric flow rate ratio between the organic and aqueous phases), total flow rate (TFR, the sum of the two phase flow rates), chip channel geometry such as diameter, number of mixing units, and layout, as well as operating temperature and buffer pH. The flow rate ratio directly affects supersaturation and nucleation kinetics, making it a core parameter in determining final particle size. The total flow rate influences mixing intensity and the shear environment. Chip geometry determines mixing efficiency and pressure drop characteristics. Temperature affects lipid phase behavior and mixing dynamics. By applying systematic DoE studies to establish mathematical relationships between process parameters and critical quality attributes, a robust operating window can be identified. BOC Sciences’ process development team has extensive experience in microfluidic parameter optimization and can help clients rapidly establish suitable production conditions.
Selecting the right microfluidic chip requires comprehensive consideration of target production volume, particle size requirements, lipid formulation characteristics, and budget. For early-stage laboratory feasibility studies and formulation screening, chips with smaller channel dimensions and more mixing units are generally recommended to obtain narrower particle size distributions. For pilot-scale expansion, chips with larger channel dimensions or parallelized chip arrays can be selected to increase output. For high-viscosity formulations or high-concentration lipid systems, chips with optimized flow path designs are needed to ensure efficient mixing. BOC Sciences offers a full range of microfluidic equipment from R&D-grade to production-grade platforms, supported by a professional technical team that provides guidance on chip selection and process development.
Common issues in microfluidic LNP production include clogging, unstable particle size, fluctuations in encapsulation efficiency, and abnormal pressure changes. Clogging is often caused by particulate impurities in lipid solutions or precipitation from high-concentration formulations. Solutions include filtration pretreatment of raw material solutions, formulation optimization to improve solubility, and selection of chips with larger channel dimensions. Particle size instability may be related to flow control precision, solution temperature fluctuations, or chip aging; therefore, high-precision syringe pumps, temperature control systems, and regular chip replacement are recommended. Fluctuations in encapsulation efficiency require checking buffer pH, N/P ratio accuracy, and proper equilibration of each solution. BOC Sciences provides comprehensive microfluidic process support services, including troubleshooting, process optimization, and operation training.
Microfluidic LNP production technology is widely applicable to multiple nucleic acid delivery scenarios. In mRNA delivery, the gentle mixing conditions of microfluidics help protect large mRNA molecules from shear-related damage, making it a commonly used LNP preparation method for mRNA-based development programs. In siRNA and antisense oligonucleotide (ASO) delivery, microfluidics can precisely control particle size within ranges suitable for liver-targeted delivery, commonly around 60–100 nm, thereby supporting efficient cellular uptake. For delivery of gene-editing components such as Cas9 mRNA and gRNA, microfluidic technology also shows strong application potential. BOC Sciences’ microfluidic LNP production platform supports a full workflow from early-stage research to scalable production.
